drugset / Trial / NCT02501811

Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure

NCT02501811

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase II, randomized, placebo-controlled clinical trial designed to assess feasibility, safety, and effect of autologous bone marrow-derived mesenchymal stem cells (MSCs) and c-kit+ cells both alone and in combination (Combo), compared to placebo (cell-free Plasmalyte-A medium) as well as each other, administered by transendocardial injection in subjects with ischemic cardiomyopathy.

Timeline

Start
2015-10
Primary completion
2020-06-25
Completion
2020-07-22

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject c-kit+ cells Unknown 5 cells Other
Subject mesenchymal stem cells Cell therapy 150 cells Other

Indications